UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):  June 2, 2018
 
 
BIOSTAR PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 

Maryland
001-34708
20-8747899
(State or Other Jurisdiction
(Commission
(I.R.S. Employer
of Incorporation)
File Number)
Identification No.)

No. 588 Shiji Avenue
Xiangyang City, Shaanxi Province, People’s Republic of China 712046
(Address of Principal Executive Office) (Zip Code)

86-029-33686638
(Registrant’s telephone number, including area code)
                                                   N/A                                                             
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1934 (§240.12b-2 of this chapter)
Emerging growth company ☐ .

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Item 8.01            Other Events.

It has come to the attention of Biostar Pharmaceuticals, Inc., a Maryland corporation (the “Company”), that Ronghua Wang, the Company’s Chairman of the Board and Chief Executive Officer of the Company, entered into a certain a certain Share Purchase Agreement, dated as of June 2, 2018, with Waiping Liu (the “Agreement”). Under the terms of this Agreement, Ronghua Wang agreed to sell his 426,999 shares of the Company’s common stock in a private sale to Waiping Liu at the purchase price of $1.57 per share (the “Shares”). The Agreement contains certain representations and warranties by the parties thereto that are customary to the agreements of this nature. Waiping Liu (which is Hong Kong spelling of Liao Huiping’s name) is a Board member at large appointed to the Board on January 29, 2018 to fill the vacancy on the Board.
 
 
 

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
 
         
Biostar Pharmaceuticals, Inc.
   
  
     
 
By:  
/s/ Ronghua Wang
   
Ronghua Wang, Chairman and CEO
   
Date:    July 6 , 2018

Biostar Pharmaceuticals (CE) (USOTC:BSPM)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024 Haga Click aquí para más Gráficas Biostar Pharmaceuticals (CE).
Biostar Pharmaceuticals (CE) (USOTC:BSPM)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024 Haga Click aquí para más Gráficas Biostar Pharmaceuticals (CE).